US Patent Issued to SHENGKE PHARMACEUTICALS (JIANGSU) on Sept. 30 for "1H-imidazo[4,5-hquinazoline compound as protein kinase inhibitor" (Chinese, American Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,428,423, issued on Sept. 30, was assigned to SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (Suzhou, China).

"1H-imidazo[4,5-hquinazoline compound as protein kinase inhibitor" was invented by Hang Cheng (Sichuan, China), Bin Liu (San Diego), Chenggang Zhang (Jiangsu, China) and Chengzhi Yu (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is a 1H-imidazo[4,5-h]quinazoline compound of formula (I). The compound is a broad spectrum inhibitor having strong activity for cyclin-dependent kinase (CDK) and is applicable in treating cell proliferative disorder"

The patent was filed on March 30, 2018, under Application No. 16/499,771.

*For further inf...